DHODH-IN-23( —— )

Catalog No. M36042 CAS No. 1346705-53-0

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

DHODH-IN-23
Note

Research use only, not for human use.
Brief Description

DHODH-IN-23 is a DHODH inhibitor with oral activity. DHODH-IN-23 is often used in cancer research.
Description

DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer.
In Vitro

Cell Proliferation Assay Cell Line:U937, HL-60, THP-1, KG-1 and MV411 Concentration:Incubation Time:72 h Result:Inhibited cell growth with GI50s of 2.4, 2.5, 2.5, 3.5 and 7.6 μM against U937, THP-1, MV411 HL-60 and KG-1, respectively.RT-PCR Cell Line:THP-1 cells Concentration:72 h Incubation Time:0.1, 1 and 3 μM Result:Induced CDllb mRNA expression.
In Vivo

Animal Model:MV411 mouse xenograft model Dosage:30 mg/kg Administration:Oral administration, twice daily for 21 days Result:Demonstrated significant anti-tumor activity both as a single agent and in combination with Cytarabine (HY-13605) at 20 mg/kg with tumor growth inhibitions of 37 and 73% respectively.
Synonyms

——
Pathway

Metabolic Enzyme/Protease
Target

Dehydrogenase
Recptor

Dehydrogenase
Research Area

——
Indication

——

1. Srikant Viswanadha, et al. Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia. Patent WO2021079273A1.

Calculator

molnova catalog